as 11-21-2024 4:00pm EST
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | DALLAS |
Market Cap: | 8.3M | IPO Year: | N/A |
Target Price: | $77.58 | AVG Volume (30 days): | 1.5M |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -18.53 | EPS Growth: | N/A |
52 Week Low/High: | $4.11 - $21.25 | Next Earning Date: | 11-14-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
FBRX Breaking Stock News: Dive into FBRX Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Business Wire
8 days ago
TipRanks
3 months ago
Business Wire
3 months ago
Newsfile
5 months ago
CNW Group
5 months ago
GlobeNewswire
5 months ago
GlobeNewswire
5 months ago
The information presented on this page, "FBRX Forte Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.